Cargando…
CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies
Dipeptidyl peptidase IV (DPP-IV) inhibitor has been expected to be a new class of anti-diabetic agent. The present study was designed to characterize the pharmacological profiles of CMD-05, a novel DPP-IV inhibitor discovered in our laboratory, in vitro and in vivo. The IC(50) of CMD-05 on DPP-IV in...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390258/ https://www.ncbi.nlm.nih.gov/pubmed/28406239 http://dx.doi.org/10.1038/srep46628 |